Aa
Research
Do anybody have any info on this research :
Title : Design, Synthesis, and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen
Link : http://pubs.acs.org/doi/abs/10.1021/jm200696v
Title : Design, Synthesis, and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen
Link : http://pubs.acs.org/doi/abs/10.1021/jm200696v
Gilead GS 9620 is for immune recovery. It's is still in trial but don't know the progress
to stimulate endogenously anti-viral cytokines with new drugs ( called TLR-agonist).
there are some made for hcv and one of them targets trl7 and works for hbv too, we should get this one tried on hbv since already on human trial and close to market.
i posted the name somewheere in the commnity but dont remember it now it is a name like bs78...
there are some made for hcv and one of them targets trl7 and works for hbv too, we should get this one tried on hbv since already on human trial and close to market.
i posted the name somewheere in the commnity but dont remember it now it is a name like bs78...
Response from Antonio Bertoletti by email earlier this year :
I have been working on HBV immunology and new therapeutic tools for more than 20 years. However, it is not easy to translate our findings to lay persons.
I might give you some articles that you can read, but the point is that I don't directly provide comments on new compounds/tools to lay persons.
Overall I would say that we are working on some new formulation of IFN-alpha ( to increase their efficacy and lower the side effects. There are also new attempts to stimulate endogenously anti-viral cytokines with new drugs ( called TLR-agonist).
Overall I think we might have new tools in 2-3 years time.
Regards
Antonio Bertoletti
I have been working on HBV immunology and new therapeutic tools for more than 20 years. However, it is not easy to translate our findings to lay persons.
I might give you some articles that you can read, but the point is that I don't directly provide comments on new compounds/tools to lay persons.
Overall I would say that we are working on some new formulation of IFN-alpha ( to increase their efficacy and lower the side effects. There are also new attempts to stimulate endogenously anti-viral cytokines with new drugs ( called TLR-agonist).
Overall I think we might have new tools in 2-3 years time.
Regards
Antonio Bertoletti
I think that the correct spelling is Antonio Bertoletti
http://www.sics.a-star.edu.sg/research.html?sciID=1&sciType=
http://www.sics.a-star.edu.sg/research.html?sciID=1&sciType=
Stephan Urban is Mycrludex, not sure about what specific drug Bartoletti is working on.
I emailed one of the researchers and here the response :
Please know that we are aggressively searching for, creating and studying a
number of different therapeutic approaches for the management of hepatitis B
and liver cancer. The HBs antigen inhibitors represent an example. These
compounds are currently in early development, and are being evaluated in
experimental systems to determine how potent they may be in people. The
project is now the subject of a significant grant from the US government,
and we are thus hopeful we will now learn enough about it to know if it is
worthy of being advanced to human studies.
In addition, we have discovered another family of drug-like small molecules
that would work with current HBV drugs and reduce levels of HBV cccDNA, and
yet another which are potent inhibitors of HBV assembly! We also discovered
a small molecule that has activity against liver cancer cells in culture and
in animal studies, and we are working on ways to improve interferon therapy
such that cccDNA would be reduced or eliminated. We are even trying to
discover methods of detecting liver disease and liver cancer in patients
early enough to make them easy to cure. There is constant effort in our
group to initiate new projects with the focus being to help the lives of
patients.
We are not the ones only doing this, there are other groups around the world
who are developing anti-HBV peptide drugs that are already in human trials,
and looking for ways to stimulate the immune system against HBV infection.
Look for the work of Drs. Stephan Urban form Germany and Dr. Antonio
Bartoletti who is based in Singapore.
Please realize that all this work is in early stages. If sufficient support
for our Foundation continues, we are hopeful that within the next couple of
years, we will attract larger pharmaceutical interest and at least one of
these approaches will become a useful lead in helping in the battle against
HBV and liver cancer. Stay tuned!
The Hepatitis B Foundation is also here to help direct patients and their
families to information and care options. The good people who do this work
will contact you.
Take care and best of luck to you,
Andy
Andrea Cuconati, Ph.D.
Project Leader
Institute for Hepatitis and Virus Research
The Hepatitis B Foundation
Pennsylvania Biotechnology Center
Please know that we are aggressively searching for, creating and studying a
number of different therapeutic approaches for the management of hepatitis B
and liver cancer. The HBs antigen inhibitors represent an example. These
compounds are currently in early development, and are being evaluated in
experimental systems to determine how potent they may be in people. The
project is now the subject of a significant grant from the US government,
and we are thus hopeful we will now learn enough about it to know if it is
worthy of being advanced to human studies.
In addition, we have discovered another family of drug-like small molecules
that would work with current HBV drugs and reduce levels of HBV cccDNA, and
yet another which are potent inhibitors of HBV assembly! We also discovered
a small molecule that has activity against liver cancer cells in culture and
in animal studies, and we are working on ways to improve interferon therapy
such that cccDNA would be reduced or eliminated. We are even trying to
discover methods of detecting liver disease and liver cancer in patients
early enough to make them easy to cure. There is constant effort in our
group to initiate new projects with the focus being to help the lives of
patients.
We are not the ones only doing this, there are other groups around the world
who are developing anti-HBV peptide drugs that are already in human trials,
and looking for ways to stimulate the immune system against HBV infection.
Look for the work of Drs. Stephan Urban form Germany and Dr. Antonio
Bartoletti who is based in Singapore.
Please realize that all this work is in early stages. If sufficient support
for our Foundation continues, we are hopeful that within the next couple of
years, we will attract larger pharmaceutical interest and at least one of
these approaches will become a useful lead in helping in the battle against
HBV and liver cancer. Stay tuned!
The Hepatitis B Foundation is also here to help direct patients and their
families to information and care options. The good people who do this work
will contact you.
Take care and best of luck to you,
Andy
Andrea Cuconati, Ph.D.
Project Leader
Institute for Hepatitis and Virus Research
The Hepatitis B Foundation
Pennsylvania Biotechnology Center
Thanks for your effort in getting info on this research. Gives all of us hope that HBV will be history in the future. Thanks all
I made enquiry about this to the HBF. Here is a response from Prof Block, one of the authors of the paper and president of HBF, related through Maureen M. Kamischke,Social Media Coordinator, HBF:
Thank you for the interest in the HBF research programs. We are aggressively searching for, creating and studying a number of different therapeutic approaches for the management of hepatitis B and liver cancer. The HBs antigen inhibitors represent an example. This drug is currently in early development, and is being evaluated in experimental systems for its efficacy. It is now the subject of a significant NIH grant, and we are thus hopeful we will now learn enough about it to know if it is worthy of being advanced to human studies. In addition, we have discovered several other small molecules that are potent inhibitors of HBV assembly, and another family may help interferon and reduce HBV cccDNA! We also discovered a small molecule that has activity against liver cancer cells in culture and in animal studies. These are all in early stages, however. If sufficient support continues, we are hopeful that within the next couple of years, we will attract larger pharmaceutical interest and at least one of these approaches will become a useful lead in helping in the battle against HBV and liver cancer. Stay tuned!
Thank you for the interest in the HBF research programs. We are aggressively searching for, creating and studying a number of different therapeutic approaches for the management of hepatitis B and liver cancer. The HBs antigen inhibitors represent an example. This drug is currently in early development, and is being evaluated in experimental systems for its efficacy. It is now the subject of a significant NIH grant, and we are thus hopeful we will now learn enough about it to know if it is worthy of being advanced to human studies. In addition, we have discovered several other small molecules that are potent inhibitors of HBV assembly, and another family may help interferon and reduce HBV cccDNA! We also discovered a small molecule that has activity against liver cancer cells in culture and in animal studies. These are all in early stages, however. If sufficient support continues, we are hopeful that within the next couple of years, we will attract larger pharmaceutical interest and at least one of these approaches will become a useful lead in helping in the battle against HBV and liver cancer. Stay tuned!
It seems to be a joint research between Chinese scientists, Hepatitis B Foundation (HBF) and an American Pharma. Add to watch list.
it seams that the approach is similar.
and it seams that they are working on this form some years. (I made a quick search for triazolopyrimidine hbv and i receive some data from 2006 )
it is a intresting option and we should have a eye on it.
and it seams that they are working on this form some years. (I made a quick search for triazolopyrimidine hbv and i receive some data from 2006 )
it is a intresting option and we should have a eye on it.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
